Toggle light / dark theme

The Inaugural Rejuvenation Startup Summit 2022, brought to you by the Forever Healthy Foundation, took place with over 400 participants from over 30 countries in October. It is a vibrant networking event that aims to accelerate the development of the rejuvenation biotech industry. The Summit brings together startups, members of the longevity venture capital / investor ecosystem, and researchers interested in founding or joining a startup – all aiming to create therapies to vastly extend the healthy human lifespan. We started to publish videos with a first set of selected speakers on the 2022 summit:

Foresight Biotech & Health Extension Meeting sponsored by 100 Plus Capital.
Program & apply to join: https://foresight.org/biotech-health-extension-program/

This video was recorded at the Foresight Longevity Workshop.

Join us:
► Twitter: https://twitter.com/foresightinst.
► Facebook: https://www.facebook.com/foresightinst.
► Instagram: https://www.instagram.com/existentialhope/
► LinkedIn: https://www.linkedin.com/company/foresight-institute.

If you enjoy what we do please support us via Patreon: https://www.patreon.com/foresightinstitute.
If you’re interested in joining these meetings consider donating through our donation page: https://foresight.org/donate/

Foresight Institute advances technologies for the long-term future of life, focusing on molecular machine nanotechnology, biotechnology, and computer science.

Subscribe for videos concerning our programs on Molecular Machines, Biotechnology & Health Extension, Intelligent Cooperation, Neurotech, Space, and Existential Hope.

ROS are short lived molecular species containing an unpaired electron which makes them highly reactive as they search for another electron to pair with, and in the process can damage biomolecules such as DNA, proteins and lipids54. ROS induced oxidative stress is known to have multiple deleterious effects on host cells55. However, we have reported that, paradoxically, when ROS is artificially generated outside the cell in the extracellular spaces of the body, they can have wide ranging therapeutic effects18,19,20,26,27. Admixing R with Cu leads to generation of oxygen radicals by virtue of the ability of R to reduce Cu (II) to Cu (I)23,25. Oxygen radicals that are generated in the stomach upon oral administration of R–Cu are apparently absorbed to have systemic effects in the form of deactivation/eradication of extracellular cfChPs. We have shown that cfChPs have wide-ranging damaging effects on host cells. For example, cfChPs can readily enter into the healthy cells to damage their DNA, activate inflammatory cytokines and promote apoptosis via the mitochondrial pathway13,14. Given that 1 × 109–1 × 1012 cells die in the body every day56,57, we have hypothesised that repeated and lifelong assault on healthy cells by cfChPs derived from the dying cells may be the underlying cause of ageing15,16. In support of this hypothesis we show in this article that prolonged oral administration of R–Cu to ageing mice down-regulated multiple biological hallmarks of ageing and neurodegeneration by virtue of its ability to deactivate cfChPs. Our results suggest that R–Cu may qualify as an ideal anti-ageing agent since it has the potential to simultaneously retard or delay the many conditions that are associated with ageing2. To be globally applicable, an ideal anti-ageing agent should also be inexpensive and non-toxic—the two criteria that are also met by R–Cu. The latter can be easily administered orally, and both R and Cu are already approved for human use. An illustrated summary of the study design and the mechanisms by which R–Cu generated oxygen radicals eradicate cfChPs from brain micro-environment leading to down-regulation of ageing hallmarks is provided in Fig. 10.

The mechanism(s) by which R–Cu down-regulates the multiple biological hallmarks of ageing and neurodegeneration needs elaboration. Reversal of telomere shortening by R–Cu may suggest that telomere shortening could be a consequence of DNA damage inflicted by cfChPs which shear off telomere ends causing them to shorten. We observed differential effects between female and male mice with respect to telomere abnormalities. R–Cu effects in preventing telomere abnormalities in female mice were statistically significant for all parameters tested, while this was not the case in male mice. The biological explanation for this discrepant finding remains to be determined. Breakage of telomere ends may also help to explain our detection of persistent γ-H2AX signals in telomere regions of brain cells (DNA-SCARS)—an established signature of senescence43. The bare chromosomal ends can fuse with each other to lead to chromosomal instability and aneuploidy48, as was detected in our study.

Just a quick vid. He mentions the hope of replacing current gene therapy with a pill or three which I heard Cynthia Kenyon say many years ago.


Dr David Sinclair talks about longevity genes, genes therapies and his works on resetting the eyes in this short clip.

David Sinclair is a professor in the Department of Genetics and co-director of the Paul F. Glenn Center for the Biology of Aging at Harvard Medical School, where he and his colleagues study sirtuins—protein-modifying enzymes that respond to changing NAD+ levels and to caloric restriction—as well as chromatin, energy metabolism, mitochondria, learning and memory, neurodegeneration, cancer, and cellular reprogramming.

Dr David Sinclair has suggested that aging is a disease—and that we may soon have the tools to put it into remission—and he has called for greater international attention to the social, economic and political and benefits of a world in which billions of people can live much longer and much healthier lives.

Dr David Sinclair is the co-founder of several biotechnology companies (Life Biosciences, Sirtris, Genocea, Cohbar, MetroBiotech, ArcBio, Liberty Biosecurity) and is on the boards of several others.

Alzheimer’s disease (AD) is a debilitating progressive illness that begins with mild memory loss and slowly destroys cognitive function and memory. It currently has no cure and is predicted to affect over 100 million people worldwide by 2050. In the United States, AD is the leading cause of dementia in older adults and the 7th most common cause of death, according to the National Institute on Aging.

Ongoing Alzheimer’s research is focused on two key neurotoxic proteins: amyloid beta (Aβ) and tau. Although these proteins have been shown to be associated with AD, the levels of Aβ and tau do not consistently explain or correlate with the severity of cognitive decline for some people with the disease.

Investigators at Brigham and Women’s Hospital, a founding member of the Mass General Brigham healthcare system, set out to identify other proteins that may be directly involved with fundamental aspects of AD, like synaptic loss and neurodegeneration. They exposed laboratory neurons to human brain extracts from about 40 people who either had AD, were protected from AD despite having high Aβ and tau levels, or were protected from AD with little or no Aβ and tau in their brains.

(http://www.pharma.unizg.hr/en/about-us/staff/gordan–lauc, 450.html) is Professor of Biochemistry and Molecular Biology at the University of Zagreb, Faculty of Pharmacy and Biochemistry, and Founder and CEO of Genos Ltd. (https://genos-glyco.com/), a research-intensive SME located in Zagreb, Croatia with core of expertise in molecular genetics and glycomics (The comprehensive study the entire complement of sugars, whether free or present in more complex molecules of an organism) and they perform contract research, contract analysis and service for numerous universities, hospitals and private individuals in Europe and overseas.

Prof. Dr. Lauc also is CSO of GlycanAge LTD (https://glycanage.com/), a company that has developed a ground-breaking test that analyses your personal glycobiome for insights in improving your health and monitoring your biological age, and Co-Director of the Human Glycome Project (https://human-glycome.org/).

Prof. Dr. Lauc graduated with a degree in molecular biology at the University of Zagreb Faculty of Science in 1992, and obtained Ph.D. in Biochemistry and the University of Zagreb in 1995. He got his postdoctoral training at the Institute for Medical Physics and Biophysics in Münster and Johns Hopkins University in Baltimore. Since 1993 he has been employed at the Faculty of Pharmacy and Biochemistry in Zagreb. Between 1998 and 2010 he was also part-time employed at the University of Osijek School of Medicine where he founded a DNA laboratory for the identification of war victims and also served as Vice-Dean for Science between 2001 and 2005.

Prof. Dr. Lauc is author of over 100 research papers published in international journals and six international patents. He was invited to lecture at numerous international conferences, elected for visiting professor at the Johns Hopkins University and in 2011 also inducted in the prestigious Johns Hopkins Society of Scholars. If 2012 he was appointed Honorary Professor at the University of Edinburgh and Adjunct Professor at the Edith Cowan University in Perth.

Prof. Dr. Lauc chaired a number of conferences, including the “European Science Foundation Exploratory Workshop on Glycoscience” which resulted in the creation of the “European Glycoscience Forum”.

Prof. Dr. Lauc was a chairman of the committee that prepared Croatian National Action plan for the increased investment in research in development (2007), and was a member of the National Science Council between 2009 and 2013 and also and President of the National Council for Natural Sciences. He is a President-elect of the International Glycoscience Organization and member of the Steering Committee of the European Glycoscience Forum.